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Background: We are using ACI and BN rats, which differ markedly in their susceptibility to 17β-estradiol
(E2)-induced mammary cancer, to identify genetic variants and environmental factors that determine mammary
cancer susceptibility. The objective of this study was to characterize the cellular and molecular responses to E2 in
the mammary glands of ACI and BN rats to identify qualitative and quantitative phenotypes that associate with
and/or may confer differences in susceptibility to mammary cancer.
Methods: Female ACI and BN rats were treated with E2 for 1, 3 or 12 weeks. Mammary gland morphology and
histology were examined by whole mount and hematoxylin and eosin (H&E) staining. Cell proliferation and
epithelial density were evaluated by quantitative immunohistochemistry. Apoptosis was evaluated by quantitative
western blotting and flow cytometry. Mammary gland differentiation was examined by immunohistochemistry.
Gene expression was evaluated by microarray, qRT-PCR and quantitative western blotting assays. Extracellular matrix
(ECM) associated collagen was evaluated by Picrosirius Red staining and Second Harmonic Generation (SHG)
microscopy.
Results: The luminal epithelium of ACI rats exhibited a rapid and sustained proliferative response to E2. By contrast,
the proliferative response exhibited by the mammary epithelium of BN rats was restrained and transitory. Moreover,
the epithelium of BN rats appeared to undergo differentiation in response to E2, as evidenced by production of
milk proteins as well as luminal ectasia and associated changes in the ECM. Marked differences in expression of
genes that encode proteins with well-defined roles in mammary gland development (Pgr, Wnt4, Tnfsf11, Prlr, Stat5a,
Areg, Gata3), differentiation and milk production (Lcn2, Spp1), regulation of extracellular environment
(Mmp7, Mmp9), and cell-cell or cell-ECM interactions (Cd44, Cd24, Cd52) were observed.
Conclusions: We propose that these cellular and molecular phenotypes are heritable and may underlie, at least in
part, the differences in mammary cancer susceptibility exhibited by ACI and BN rats.
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In spite of recent advances in diagnosis and treatment,
breast cancer remains the second leading cause of
cancer-related death in women in the United States. The
existence of multiple subtypes of breast cancer, each with
unique clinical and/or molecular characteristics, is now
well established [1,2]. Multiple genetic and environmen-
tal factors contribute to breast cancer development, and
it is becoming increasingly clear that development of
each breast cancer subtype is influenced by different sets
of factors. Known risk factors include a family history of
breast cancer, cumulative exposure to endogenous and
exogenous estrogens and breast mammographic density
[3-9]. Although several genes have been identified that
significantly impact breast cancer risk when mutated or
aberrantly expressed, only a small fraction of the overall
population risk can be attributed to these genes [10-12].
Similarly, the genetic determinants of responsiveness to
estrogens and mammographic density remain poorly
defined.
We are using inbred ACI (August x Copenhagen, Irish),
COP (Copenhagen) and BN (Brown Norway) rats to define
the mechanisms through which estrogens contribute to
mammary cancer development and identify genetic deter-
minants of susceptibility to mammary cancer. When
treated continuously with 17β-estradiol (E2), female ACI
rats develop mammary carcinoma at an incidence ap-
proaching 100% [13]. The mammary cancers that develop
in E2 treated ACI rats express estrogen receptor-α (ERα)
and progesterone receptor (Pgr), are dependent upon E2
for continued growth and survival, and frequently exhibit
chromosome copy number changes and instability [14-16].
Development of mammary cancer in E2 treated ACI rats is
dramatically inhibited by concurrent treatment with tam-
oxifen, indicating a requirement for one or more estrogen
receptor mediated mechanisms in tumor development
[17,18]. Interestingly, tumor development in ACI rats also
requires the action of progesterone [13,19]. By contrast,
COP and BN rats are resistant to E2-induced mammary
cancer [20-22]. Multiple genetic determinants of suscepti-
bility to E2-induced mammary cancer, designated Emca1
(Estrogen-induced mammary cancer 1) through Emca9,
have been mapped in crosses between susceptible ACI rats
and resistant COP or BN rats [21-24]. Each of the mapped
quantitative trait loci (QTL) encompass segments of the rat
genome that are orthologous to regions of the human
genome linked to breast cancer risk in genome wide associ-
ation studies (GWAS). Together, these data indicate that
the ACI rat model of E2-induced mammary cancer is a
physiologically relevant model for studying the molecular
etiology of luminal type breast cancers.
The purpose of this study was to define, both qualita-
tively and quantitatively, the manner in which the mam-
mary glands of susceptible ACI and resistant BN ratsrespond to E2. Dramatic differences in multiple cellular
and molecular responses to E2 were observed when these
two inbred rat strains were compared. These differences
contributed to and/or were associated with differences in
epithelial density, mammary gland differentiation and
ECM, as well as differential expression of many genes of
known significance to mammary gland development. We
propose that the observed differences in responsiveness
of the mammary gland to E2 represent phenotypes that
underlie the documented strain differences in susceptibil-
ity to mammary cancer and may also contribute to and/
or serve as biomarkers of breast cancer risk in humans.
Methods
Care and treatment of animals
All procedures involving live animals were approved by
the Animal Care and Use Committee of the University
of Wisconsin-Madison. Female ACI and BN rats were
purchased from Harlan Laboratories (Indianapolis, IN). As
described previously, SilasticTM tubing implants (Dow
Corning, Midland, MI), empty or containing 27.5 mg of E2
(Sigma-Aldrich, St. Louis, MO), were made and placed
surgically into the interscapular region of 9 week old rats;
these implants release hormone continuously and maintain
circulating E2 at levels normally observed in pregnant rats
[13,25]. Groups of sham treated (empty implant) control
and E2 treated rats were euthanized 1, 3 or 12 weeks later.
Each rat was injected with 5-bromo-2′-deoxyuridine (BrdU,
Sigma-Aldrich), administered intraperitoneally in phos-
phate buffered saline (PBS) at 50 mg/kg body weight, four
hours before termination of the experiments. Mammary
tissues were collected and processed as described below to
quantify various cellular and molecular phenotypes.
Evaluation of mammary gland morphology and histology
Mammary gland whole mounts were generated to evalu-
ate gland morphology. The left inguinal and abdominal
mammary glands were collected, stretched flat onto
Apex Superior Adhesive Slides (Leica Biosystems, Buffalo
Grove, IL), and fixed in 25% glacial acetic acid in ethanol
overnight at room temperature. The glands were stained
overnight at room temperature in 2 mg/ml carmine
(Sigma-Aldrich) and dehydrated in 70%, 95% and 100%
ethanol [26]. Finally, the glands were cleared by submer-
sion in xylene, approximately 100 ml per slide, which
was changed daily until the epithelial structures could be
clearly observed. The whole mounts were photographed
using an SZX9 dissecting microscope equipped with a
C-7070 digital camera (Olympus, Center Valley, PA).
To evaluate mammary gland histology, the glands were
collected and fixed overnight at room temperature in 4%
paraformaldehyde. The fixed tissues were then transferred
to 70% ethanol, processed and embedded in paraffin. Sec-
tions (5.0 microns) were cut, mounted on slides, stained
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Photomicrographs were obtained using a Zeiss Axio
Imager.M2 microscope equipped with an AxioCam HRc
digital camera (Carl Zeiss, Thornwood, NY).Quantitative immunohistochemistry (IHC)
Paraffin embedded mammary tissues were cut to 5.0 mi-
crons, mounted on slides, deparaffinized in xylene and
rehydrated stepwise in ethanol at decreasing concentration
(100% (twice), 95%, 90%, 80%, 70%, 50%). The tissues were
permeabilized in 0.5% Triton X-100 in PBS and antigens
were retrieved by boiling in 0.01 M sodium citrate (pH 6.0)
for 10 minutes. The sections were then incubated in 10%
goat serum (diluted in PBS) for 1 h at room temperature;
incubated overnight at 4°C in a primary antibody, diluted
as described in Additional file 1: Table S1; rinsed three
times for 5 minutes each with 0.1% Tween-20 in PBS
(0.1% PBST); incubated with the appropriate secondary
antibody (Additional file 1: Table S1) for 1 hour at
room temperature; rinsed three times for 5 minutes
each in 0.1% PBST; and incubated in Prolong Gold
Anti-Fade plus 4′,6-diamidino-2-phenylindole (DAPI,
Life Technologies, Carlsbad CA). The stained sections
were visualized by fluorescence microscopy using an
Axio Imager.M2 microscope equipped with an Apotome
structured illumination imaging system and an AxioCam
MRm digital camera (Carl Zeiss).
Quantitative IHC was performed using a Vectra™ multi-
spectral fluorescence imaging system running Nuance 3.0.0
imaging software (Caliper Life Sciences, Hopkinton, MA).
High-resolution (1,360 × 1,024 pixel), 8-bit grayscale images
were acquired automatically every fourth field over the
entire tissue section. The nuclear compartment was defined
by DAPI (blue). Cytokeratin 5 (K5) and cytokeratin 8 (K8)
were visualized using secondary antibodies conjugated with
Alexa Fluor 488 (green) and Alexa Fluor 546 (red), respect-
ively. Cells that incorporated BrdU during the S phase of
the cell cycle were visualized using a secondary antibody
conjugated with Alexa Fluor 647 (yellow). An unstained
section of mammary tissue was used to build a spectral
library for autofluorescence. Sections stained with a single
chromogen were used to build spectral libraries for DAPI,
Alexa Fluor 488, Alexa Fluor 546 and Alexa Fluor 647.
These libraries allowed the different fluorophores to be
distinguished from one other and from autofluorescence
without spectral overlap. The inform 1.2 analysis software
(Caliper Life Sciences) was trained to distinguish epithelium
from non-epithelium and to define subcellular compart-
ments (nucleus, cytoplasm and membrane) and was subse-
quently used to quantify the fraction of luminal epithelial
cells in the S phase of the cell cycle (K8/BrdU double posi-
tive) as well as the number of luminal epithelial cells
(DAPI/K8 double positive) per field.Quantification of apoptosis
Freshly isolated inguinal and abdominal mammary glands
were cut into small segments and digested for 6 hours at
37°C in Dulbecco’s modified Eagle’s medium/F12 (DMEM/
F12, Life Technologies) supplemented with 5% fetal bovine
serum (FBS, Life Technologies), 300 U/ml collagenase
(STEMCELL Technologies, Vancouver, BC) and 100 U/ml
hyaluronidase (STEMCELL Technologies). The result-
ing organoids were reduced to single cells by digestion
with 0.25% Trypsin (STEMCELL Technologies), 5mg/
ml Dispase (STEMCELL Technologies) and 5,000 U/ml
DNase I (Roche Applied Science, Indianapolis, IN). The
dissociated cells were filtered through 25 μm cell
strainers and were stained with Alexa Fluor 647 labeled
Annexin V conjugate (Life Technologies) and propidium
iodide (PI, Sigma-Aldrich) [27]. The stained cells were
analyzed using a FACSCalibur flow cytometer running
CellQuestPro version 5.2.1 data acquisition software
(BD Biosciences, San Jose, CA). Subsequent data ana-
lyses were performed using FlowJo version 9.6 (TreeStar
Inc., Ashland, OR).Evaluation of gene expression
Gene expression profiles were defined for ACI and BN
rats that had been treated with E2 for 12 weeks (n = 5
rats per group) using Affymetrix Rat Genome 230 2.0
GeneChips Arrays (Affymetrix, Santa Clara, CA) as
described previously [24]. The primary microarray data
have been deposited in Gene Expression Omnibus
under accession number GSE49548. Gene ontology
enrichment analyses were performed using Ontologizer
2.0 as described previously [24].
Differential expression of selected genes was further
evaluated by quantitative real-time PCR (qRT-PCR).
Total RNA was isolated from frozen mammary tissue
using an Aurum Total RNA Fatty and Fibrous Tissue
Kit (Bio-Rad, Hercules, CA). Single-stranded cDNA was
synthesized using 1 μg RNA and an iScript cDNA
Synthesis Kit (Bio-Rad). qRT-PCR was performed using
TaqMan Gene Expression Master Mix (Life Technologies),
a CFX96 multicolor real-time PCR detection system
(Bio-Rad) and pre-designed TaqMan primers and
probes (Integrated DNA Technologies, Coralville, IA):
Pgr (Rn.PT.53.36352803), Wnt4 (Rn.PT.53.34796012),
Tnfsf11 (Rn.PT.53.13125438), Spp1 (Rn.PT.51.10587746.
g), Lcn2 (Rn.PT.51.11294783), Mmp7 (Rn.PT.51.1049
9639), Mmp9 (Rn.PT.53a.7321135), Lef1 (Rn.PT.51.535
4713) and Actb (Rn.PT.51.13516462). The PCR program
was 95°C for 10 minutes followed by 40 cycles at 95°C
for 10 seconds and 60°C for 45 seconds. The data for
each gene were analyzed using the ΔΔCq method and
CFX Manager Software version 2.1 (Bio-Rad) and are
illustrated relative to expression levels of Actb.
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Frozen mammary tissues were homogenized with
PowerGen Model 35 Handheld Homogenizer (Thermo
Fisher Scientific, Waltham, MA) in lysis buffer contain-
ing 25 mM HEPES (pH 7.4), 300 mM NaCl, 1.5 mM
MgCl2, 1 mM EGTA, 0.2 mM Na3VO4, 50 mM glycero-
phosphate, 0.5% Triton X-100 and 1% Halt Proteinase
and Phosphatase Inhibitor Cocktail (Thermo Fisher
Scientific). The lysates were centrifuged at 12,000g for
30 min, the supernatants were collected and protein
concentration was determined using BCA Protein Assay
Reagent (Thermo Fisher). Spp1 and Lcn2 were quantified
using the Odyssey Imaging System (LI-COR, Lincoln,
NE). Briefly, mammary proteins were separated by SDS-
PAGE and transferred to Immobilon-FL PVDF membranes
(Millipore, Billerica, MA). The blots were incubated with
Odyssey blocking buffer (LI-COR) for 1 h at room
temperature; incubated overnight at 4°C with primary
antibody diluted in Odyssey blocking buffer containing
0.1% Tween-20 as described in Additional file 1: Table
S1; washed four times for 5 minutes each with 0.1%
PBST; incubated with the appropriate IRDye-conjugated
secondary antibody (Additional file 1: Table S1) for 1 h
at room temperature in the dark; washed four times for
5 minutes each with 0.1% PBST; imaged and quantified.
Cleaved caspase 3, Mmp7 and Mmp9 were quantified
using the ChemiDoc XRS + imaging system (Bio-Rad).
SDS-PAGE and protein transfer were performed as de-
scribed above. The blots were then incubated in PBS
containing 5% non-fat milk and 0.1% Tween-20 for 1
hour at room temperature; incubated overnight at 4°C
in the same buffer containing primary antibody as indi-
cated in Additional file 1: Table S1; washed four times
for 5 minutes each with 0.1% PBST; incubated in horse-
radish peroxidase conjugated secondary antibody for 1
h at room temperature (Additional file 1: Table S1); and
washed four times for 5 minutes each with 0.1% PBST.
The proteins were visualized using SuperSignal West
Dura Chemiluminescent Substrate (Thermo Fisher),
imaged and quantified using Image Lab 4.0.1 software
(Bio-Rad). All blots were also probed with an antibody
to β-actin (Additional file 1: Table S1) and expression of
each protein of interest was normalized relative to the
amount of β-actin.
Evaluation of extracellular matrix collagen
Paraffin embedded mammary tissues were sectioned,
deparaffinized, rehydrated and stained with Picrosirius
Red (Sigma-Aldrich) to visualize ECM collagen; counter
stained with Fast Green FCF (Sigma-Aldrich) to visualize
non-collagenous cellular and matrix constituents; imaged
and photographed using a BX60 epifluroescence micro-
scope equipped with a DP25 digital camera and cellSens
digital imaging software (Olympus). Halogen bulb basedillumination was used for polarized light and brightfield mi-
croscopy. SHG for visualization of collagen was conducted
on a custom multiphoton laser scanning microscope
[28,29]. All SHG images were collected at a wavelength of
890nm with a 445 nm (20 nm bandpass) filter (Semrock,
Rochester, NY).
Statistical analysis of data
Differences between groups were evaluated using Stu-
dent’s two-tailed t-test. Significance was established at
p < 0.05.
Results
Rat strain specific effects of 17β-estradiol on mammary
gland morphology and histology
Mammary gland morphology and histology were evalu-
ated at 1, 3 and 12 weeks relative to the initiation of
treatment at 9 weeks of age to determine whether or not
the mammary glands of susceptible ACI rats and resist-
ant BN rats differ in their responsiveness to E2. Figure 1A
illustrates a typical whole mount of the left abdominal
and inguinal mammary glands from a 10 weeks old, ovary
intact, ACI rat. Figure 1B represents higher magnification
images of the region of the abdominal mammary gland of
sham or E2 treated ACI or BN rats represented by the
rectangle in Figure 1A. The mammary glands of sham
treated ACI and BN rats were comprised of elongated,
branched ductal structures that extended to the margins
of the mammary fat pad and terminated in small clusters
of epithelial cells. No discernible differences in mammary
gland morphology were observed between sham treated
ACI rats and BN rats. E2 treatment induced a marked
increase in the size and complexity of the epithelial struc-
tures in the mammary glands of ACI rats. This response
was observed within 1 week of initiation of E2 treatment
and remained apparent following 3 and 12 weeks of treat-
ment. By contrast, the impact of E2 treatment on the size
and complexity of the epithelial structures in BN rats was
modest (Figure 1B).
Examination of H&E stained sections demonstrated that
the mammary glands of sham treated ACI and BN rats
consisted of ducts, terminal duct lobule units and
associated ECM embedded within the mammary fat pad
(Figure 1C). No discernible differences in mammary gland
histology were observed between sham treated ACI and
BN rats at any of the three time points. The mammary
glands of E2 treated ACI rats consisted of large clusters of
epithelial cells organized around the mammary ducts, con-
sistent with induction of lobuloalveolar hyperplasia. This
hyperplastic response to E2 was apparent within 1 week of
initiation of treatment and appeared similar following 3 and
12 weeks of treatment. Although E2 treatment led to an in-
crease in the apparent size of the epithelial structures in the
mammary glands of BN rats, this resulted primarily from
Figure 1 Rat strain-specific effects of 17β-estradiol on mammary gland morphology and histology. A, Representative whole mount of
abdominal/inguinal mammary glands from a 10 weeks old ACI female. Left, anterior. Right, posterior. Up, medial. Down, lateral. The rectangle
illustrates the approximate region of the abdominal gland illustrated in Panels B. Scale bar, 5mm. B, Representative images of mammary gland
whole mounts from ACI and BN rats, either sham treated (Ctrl) or treated with E2 for 1, 3 or 12 weeks (n = 3). Scale bars, 2mm. C, Representative
images of mammary tissues, sectioned and stained with hematoxylin and eosin, from ACI and BN rats treated as described in Panels B (n≥ 5).
Scale bars, 100 μm.
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tion of lobuloalveolar hyperplasia. The luminal ectasia was
apparent within 1 week of initiation of E2 treatment and
remained the predominant feature in the mammary glands
of E2 treated BN rats following 3 and 12 weeks of treat-
ment. Together, these data illustrate remarkable differences
in the cellular responses to E2 within the mammary glands
of ACI and BN rats that are discernible within 1 week of
initiation of hormone treatment.
Rat strain specific effects of 17β-estradiol on mammary
cell proliferation and differentiation, but not apoptosis
Proliferation in defined mammary cell populations was
quantified by IHC using antibodies to K5, a marker ofbasal epithelium, K8, a marker of luminal epithelium,
and BrdU, a marker for cells that transited the S phase
of the cell cycle within the 4 hours preceding euthanasia.
Representative images from ACI and BN rats treated for
1 week with E2 and age matched, sham treated, control
rats are illustrated in Figure 2A. Images generated at the
3 week and 12 week time points are appended as
Additional file 2: Figure S1A and S1B, respectively. The
mammary epithelia of both control and E2 treated ACI
and BN rats were comprised of an outer layer of basal
cells surrounding the inner luminal cells. Quantification
by Vectra system demonstrated that the fraction of BrdU
positive cells in the luminal epithelium of sham treated
ACI and BN rats was below 1.0% at each of the time
Figure 2 Rat strain-specific effects of 17β-estradiol on mammary epithelial cell proliferation. A, Representative fluorescent images of
mammary tissues from ACI and BN rats, either sham treated (Ctrl) or treated with E2 for 1 week (n = 3). Column 1, nuclei identified by staining
DNA with 4′,6-diamidino-2-phenylindole (DAPI, blue). Column 2, basal epithelial cells were identified by immunostaining for cytokeratin 5 (K5,
green). Column 3, luminal epithelial cells were identified by immunostaining for cytokeratin 8 (K8, red). Colum 4, cells transiting S phase were
identified by immunostaining for BrdU (yellow). Column 5, merged images from columns 1 through 4. Scale bars, 50 μm. B, The number of
luminal epithelial cells (K8 positive) in S phase (BrdU positive) was quantified using a VectraTM multispectral fluorescence imaging system and
illustrated as the percentage of total luminal epithelial cells. C, The number of luminal epithelial cells per field was quantified as an indicator of
epithelial density. Each data bar in Panels B and C represents the mean ± standard error of the mean (SEM, n = 3). 1, p < 0.05 for comparison of E2
treated vs. sham treated rats of same strain. 2, p < 0.05 for comparison of E2 treated BN vs. treated ACI rats.
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2B). Treatment with E2 dramatically induced proliferation
within the luminal epithelium of ACI rats. The fraction of
luminal cells staining positive for BrdU was increased to
10.6%, 8.2% and 5.8% in ACI rats treated with E2 for 1, 3
and 12 weeks, respectively. By contrast, E2 treatment
increased the fraction of luminal cells staining positive for
BrdU in BN rats to only 3.2% following 1 week and 1.8%
following 3 weeks of treatment, and no significant increase
was observed in BN rats treated with E2 for 12 weeks
(Figure 2A and 2B). The fraction of S phase cells in the
luminal epithelium of E2 treated ACI rats was significantly
greater than in treated BN rats at each of the three time
points. The difference in induction of luminal epithelial
cell proliferation in these two rat strains was clearlyreflected in the morphological and histological differences
described above (Figure 1B, 1C and 2A), as well as in
differences in epithelial density measured by quantifying
the number of luminal epithelial cells per microscopic
field. This indicator of epithelial density did not differ
between sham treated ACI and BN rats at any of the time
points examined (Figure 2C). The number of luminal
epithelial cells per field was increased more than 6-fold in
ACI rats treated with E2 for 1, 3 or 12 weeks, relative to
age-matched control ACI rats. By contrast, the number of
luminal epithelial cells per field was increased 1.7-, 2.4-
and 3.2-fold in BN rats treated for 1, 3 and 12 weeks,
respectively, relative to control BN rats. Together, these
data demonstrate that the proliferative response of the
luminal epithelium of ACI rats to E2 is markedly greater
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was not quantified because the basal cells in E2 treated
rats assumed an elongated morphology that made it diffi-
cult to assign a specific nucleus to the cells staining posi-
tive for K5.
Apoptosis within the mammary gland was evaluated
using two independent methods. In the first, the levels
of the activated 17 and 19 kDa forms of caspase 3 were
quantified by western blotting. No significant differ-
ences in the levels of cleaved caspase 3 were observed
when mammary glands from E2 treated ACI and BN
rats were compared (Figure 3A and 3B). Binding of
Annexin V to dispersed mammary cells was quantified
by flow cytometry as a second indicator of apoptosis.
Approximately 20% of cells isolated from mammary
glands of ACI and BN rats that were treated with E2 for
3 weeks stained positive for Annexin V and negative for
PI (Figure 3C and 3D). When an involuting mammary
gland from an ACI rat (3 days post-lactation) was evalu-
ated as a positive control, approximately 80% of cells
isolated cells stained positive for Annexin V. Together,
these data suggest that the levels of apoptosis in the
mammary glands of E2 treated ACI and BN rats did not
differ significantly.Figure 3 No discernable effect of rat strain on apoptosis in the mamm
prepared from mammary glands of ACI and BN rats, treated with E2 for 1,
and 17 kDa fragments) of caspase 3 (n = 3). B, The amount of cleaved casp
and normalized to the amount of β-actin. Each data bar represents the me
glands of ACI and BN rats, treated with E2 for 3 weeks, were stained with A
isolated from an involuting mammary gland (3 days post-lactation) were st
the number of apoptotic cells (positive for annexin V, negative for PI) expreIHC was performed using an antibody to milk proteins
to evaluate mammary gland differentiation and to define
the nature of the luminal ectasia observed in E2 treated
BN rats (Figure 4). Immunoreactive milk proteins were
detected in the lumens of sham treated ACI and BN rats
and the amount of immunostaining did not differ
discernibly between these rat strains. Milk proteins were
also detected in the lumens of ACI rats treated with E2
for 1, 3 and 12 weeks. The most prominent feature of
the mammary glands of E2 treated BN rats was the
markedly dilated lumens that contain immunoreactive
milk proteins. These data, together with data presented
above, suggest that the primary response of the ACI
mammary gland to E2 is cell proliferation, which leads
to dramatic epithelial hyperplasia. By contrast, the
primary response of the BN mammary gland to E2
appears to be differentiation to an active secretory
epithelium associated with luminal ectasia and modest
epithelial hyperplasia.
Rat strain specific effects of 17β-estradiol on gene
expression
To gain insights into the molecular mechanisms that
underlie the observed differences in responsiveness ofary gland. A, Representative western blots of protein lysates
3 or 12 weeks, and probed with antibody to cleaved forms (19 kDa
ase 3 was quantified using a Bio-Rad ChemiDoc XRS + imaging system
an ± SEM, n = 3 biological replicates. C, Cells isolated from mammary
nnexin V and propidium iodide and analyzed by flow cytometry. Cells
ained and analyzed as a positive control. D, Each data bar represents
ssed as a percentage of total PI negative cells (mean ± SEM, n = 3).
Figure 4 Rat strain-specific effects of 17β-estradiol on luminal ectasia and expression of milk proteins. Representative fluorescent images
of mammary tissues from ACI and BN rats, either sham treated (Ctrl) or treated with E2 for 1, 3 or 12 weeks (n = 3). Nuclei were identified by
staining DNA with DAPI (blue), luminal epithelial cells by immunostaining for K8 (red), and milk proteins were identified by immunostaining using
a polyclonal antibody generated against milk specific proteins (green). Note that the mammary glands from E2 treated BN rats exhibit prominent
ectatic lumens containing immunoreactive milk protein(s). Scale bars, 50 μm.
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expression profiles were generated using total RNA
isolated from whole mammary glands from ACI and BN
rats that were treated with E2 for 12 weeks. Transcripts
corresponding to 4170 probe sets were observed to be
differentially expressed using a false discovery rate of
5%. Of these, transcripts corresponding to 2267 probe
sets were more highly expressed in mammary glands
from E2 treated ACI rats, relative to matched BN rats,
whereas transcripts corresponding to 1903 probe sets
were more highly expressed in mammary glands from
BN rats (Additional file 1: Table S2). The genome ontol-
ogy terms most strongly associated with the differentially
expressed transcripts related to immune system process/
response, cell activation/proliferation and cell surface
binding/adhesion (Additional file 1: Table S3).
Several genes that encode proteins that serve defined
roles in mammary gland development were observed to
be more highly expressed in mammary glands of E2
treated ACI rats, including Pgr, Wnt4, Tnfsf11, Areg, Prlr,
Stat5a and Gata3. Interestingly, two genes that encode
proteins that are secreted into milk and may function in
regulation of mammary gland differentiation and milk
production, Spp1 and Lcn2, were more highly expressed
in the mammary glands of BN rats. Also highly
expressed in the mammary glands of E2 treated BN rats
were multiple genes that encode proteins that regulate
the extracellular environment including Mmp7, Mmp9,
Mmp11 and Mmp12; Adam8, Adam9, Adam15 and
Adam17; and Timp1, Timp2 and Timp3. qRT-PCR was
performed for eight differentially expressed genes to
validate the microarray data. The data from these
analyses verified that Pgr, Wnt4 and Tnfsf11 were
expressed at a significantly higher level in the mammaryglands of E2 treated ACI rats, whereas Spp1, Lcn2,
Mmp7, Mmp9, and Lef1 were expressed at a significantly
higher level in the mammary glands of E2 treated BN
rats (Figure 5).
Expression of a subset of the genes that are potentially
of functional significance in relation to mammary devel-
opment, ECM and/or ECM remodeling and mammary
cancer susceptibility was further evaluated at the protein
level. Although Spp1 was expressed at similar levels in
control ACI and BN rats, expression increased in response
to E2 treatment in mammary glands of BN but not ACI
rats, resulting in significantly higher levels of Spp1 in
treated BN rats at the 3 (5.5-fold) and 12 (4.1-fold) week
time points, relative to treated ACI rats (Figure 6A and
6D). Lcn2 was virtually undetectable in mammary glands
of control and E2 treated ACI rats. By contrast, Lcn2 was
highly expressed in mammary glands of control and E2
treated BN rats (Figure 6B and 6E). Mmp7 was undetect-
able in mammary glands of control ACI and BN rats at
each of the three time points examined (data not shown),
remained undetectable in the mammary glands of ACI
and BN rats treated with E2 for 1 week, but was detected
in glands from ACI and BN rats treated with E2 for 3
(data not shown) and 12 weeks (Figure 6F and 6I). More-
over, the active 18kDa form of Mmp7 predominated over
the 25kDa proenzyme in mammary glands from BN rats
treated with E2 for 12 weeks (Figure 6F and 6I). Mmp9
was expressed at similar levels in mammary glands of con-
trol and E2 treated ACI and BN rats at the 1 and 3 week
time points (data not shown). At the 12 week time point,
Mmp9 was expressed at a higher level in E2 treated BN
rats, relative to treated ACI rats, and the active form of
Mmp9 was observed only in mammary glands from the
treated BN rats (Figure 6G and 6J).
Figure 5 Rat strain-specific effects of 17β-estradiol on mRNA expression. RNA was isolated from mammary glands of ACI and BN rats,
treated with E2 for 12 weeks. Expression of mRNAs encoded by 8 genes of interest was quantified using the ΔΔCq PCR-based method. Each data
bar represents the level of the indicated mRNA normalized to the level of β-actin mRNA (mean ± SEM, n = 3. *, p < 0.05). The differences observed
upon comparison of expression of these 8 mRNA in mammary glands from E2 treated ACI and BN rats were concordant with differences in
expression observed upon microarray analysis.
Figure 6 Rat strain-specific effects of 17β-estradiol on protein expression. Representative western blots of protein lysates prepared from
mammary glands of ACI and BN rats, treated with E2 for 1, 3 or 12 weeks, and probed with antibody to Spp1 (Panel A), Lcn2 (Panel B) or
β-actin (Panel C). The amounts of Spp1 (Panel D) and Lcn2 (Panel E) were quantified using a LI-COR Odyssey system and expressed relative to
the amount of β-actin in the same lysate. Representative western blots of protein lysates prepared from mammary glands of ACI and BN rats,
treated with E2 for 12 weeks, and probed with antibody to Mmp7 (Panel F), Mmp9 (Panel G) or β-actin (Panel H). The amounts of the
proenzymes and active forms of Mmp7 (Panel I) and Mmp9 (Panel J) were quantified using a Bio-Rad ChemiDoc XRS + imaging system and
expressed relative to the amount of β-actin in the same lysate. Each data bar represents the mean ± SEM, n = 3 biological replicates. 1, p < 0.05,
E2 treated vs. sham treated rats of same strain. 2, p < 0.05, E2 treated BN rats compared to E2 treated ACI rats.
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matrix
Mammary tissues from ACI and BN rats were stained with
Picrosirius Red and examined using histopathology and
SHG imaging methods to evaluate ECM and associated
collagens. When examined using bright field microscopy,
all collagen types appear red, while non-collagenous tissues
and intraluminal secreta appear green. Under polarized
light, the collagen fibers are birefringent in a range of
colors from green-yellow-orange-red. When evaluated
qualitatively, mammary tissues from sham treated ACI and
BN rats did not differ discernibly with respect to the mam-
mary parenchyma, stroma, ECM or collagen (data not
shown). By contrast, the ectatic ducts uniquely present in
the mammary glands of E2 treated BN rats were generally
associated with a robust collagenous stroma (Figure 7A).
Evaluation of the ECM using SHG further established the
existence of a robust collagenous stroma surrounding
ectatic ductal structures in E2 treated BN rats. However,
the morphology and content of stromal collagen appeared
to be qualitatively and anatomically appropriate to the size
of the ducts present (Figure 7B).
Discussion
Data presented herein demonstrate that the mammary
glands of ACI and BN rats exhibited marked quantitative
and qualitative differences in their cellular and molecular
responses to E2. The primary response exhibited by ACI
rats, which are uniquely susceptible to mammary cancer
when treated with estrogens, was a robust and sustained
proliferation within the mammary epithelium. By contrast,
the proliferative response of the mammary epithelium of
BN rats, which are highly resistant to estrogen-induced
mammary cancer, was restrained and transient. This
difference in induction of cell proliferation, not a differ-
ence in apoptosis, appeared to be largely responsible for
the quantitative differences in epithelial density observed
when the mammary glands of ACI and BN rats were
compared following 1, 3 and 12 weeks of E2 treatment.
Moreover, the mammary glands of E2 treated BN rats, but
not ACI rats, exhibited qualitative phenotypes consistent
with differentiation to secretory epithelium, as well as
luminal ectasia and associated changes in collagenous
stroma. These differences in the responsiveness of the
mammary glands of ACI and BN rats to E2 were apparent
within one week of initiation of treatment, strongly
suggesting that the molecular mechanisms responsible for
the rat strain specific responses may be inherent within
the mammary glands of these inbred rat strains.
Comparison of gene expression profiles for mammary
glands of E2 treated ACI and BN rats revealed differential
expression of multiple genes that may have contributed to
the differences in luminal epithelial cell proliferation and
lobuloalveolar hyperplasia observed upon comparison ofthese rat strains. Pgr, Wnt4, Tnfsf11 (RankL), Prlr, Stat5a,
Areg and Gata3 were expressed at higher levels in mam-
mary glands of E2 treated ACI rats, relative to identically
treated BN rats. The protein products encoded by these
genes play well defined important roles in mammary
gland development. Expression of Pgr in mammary
epithelium is induced by E2 and progesterone, acting
through Pgr, plays a requisite role in stimulating lobuloal-
veolar development during pregnancy [30-32]. Moreover,
studies summarized above have demonstrated a requisite
role for progesterone in the induction of mammary cancer
development by E2 in ACI rats [13,19]. Both Wnt4 and
RankL have been demonstrated to function downstream
of Pgr in stimulating lobuloalveolar development and have
more recently been shown to be requisite paracrine medi-
ators of the actions of progesterone in the regulation of
mammary stem cell number [33-37]. Prlr and Stat5a are
both required for induction of lobuloalveolar development
by prolactin, a second major hormonal regulator of lobu-
logenesis during pregnancy [38,39]. Areg functions as an
important paracrine mediator of the actions of estrogens
and ERα on induction of mitogenesis in the mammary
epithelium [40,41]. Finally, Gata3 is required for elong-
ation of mammary ducts at puberty and maintenance of
differentiated luminal epithelium, and also acts as a posi-
tive regulator of expression of Esr1, the gene encoding
ERα [42,43]. Additional studies are needed to establish
whether differential expression of these genes is the cause
or the consequence of the observed differences in epithe-
lial cell proliferation and lobuloalveolar hyperplasia exhib-
ited by E2 treated ACI and BN rats.
Other differentially expressed genes encode protein
products that are functionally associated with mam-
mary gland differentiation, lactation and/or post-
lactational involution. Spp1 and Lcn2 are among those
genes that were most highly expressed at the mRNA
level in mammary glands of E2 treated BN rats, relative
to identically treated ACI rats. Spp1 encodes a secreted
phosphoprotein that is highly expressed in the mam-
mary gland during lactation and involution [44-46].
Spp1 has also been demonstrated to be more highly
expressed in mammary glands of parous mice and rats,
compared to nulliparous controls [47,48]. Inhibition of
Spp1 expression in the luminal epithelium of the mouse
mammary gland inhibits lobuloalveolar development,
expression of genes encoding milk proteins and milk
production [49]. Moreover, Spp1 underlies a quantita-
tive trait locus (QTL) in dairy cattle that controls milk
yield and protein content [45]. Together, these data
suggest that Spp1 regulates multiple processes in the
mammary epithelium during pregnancy, lactation and/
or mammary gland involution. Lcn2 encodes a secreted
glycoprotein that is highly expressed within the luminal
epithelium of the mammary gland during pregnancy
Figure 7 Rat strain-specific effects of 17β-estradiol on extracellular matrix and associated collagens. A, Representative images of
mammary tissues, sectioned and stained with Picrosirius Red, from ACI and BN rats treated with E2 for 1, 3 or 12 weeks (n = 3). When imaged
under bright field illumination, ECM associated collagens appear red, non-collagenous tissue and intraluminal secreta appear green. When imaged
under polarized light, collagens appear green-yellow-orange-red. Scale bars, 200 μm. B, Representative SHG images of mammary tissues from ACI
and BN rats treated with E2 for 1, 3 or 12 weeks (n = 3). Scale bars, 100 μm. Together, these images illustrate a robust collagenous stroma
associated with ectatic ducts in mammary glands of E2 treated BN rats.
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tion [50,51]. Lcn2 is known to bind a diverse group of
ligands, including retinoids, fatty acids, bacterial side-
rophores and specific MMPs. Suggested functions of
Lcn2 in the mammary gland include modulation of
inflammation and immunity, ECM remodeling and
regulation of iron homeostasis. The functional signifi-
cance of differential expression of Spp1 and Lcn2 in the
mammary glands of ACI and BN rats remains under
investigation.As noted above, luminal ectasia and associated collage-
nous stroma were qualitative phenotypes unique to the
mammary glands of E2 treated BN rats. Several genes that
encode proteins that are known to modify the extracellular
microenvironment were observed to be differentially
expressed between E2 treated ACI and BN rats. Two
examples are Mmp7 and Mmp9, both of which were
expressed and activated to a greater degree in the mam-
mary glands of BN rats, relative to ACI rats. Known func-
tions of these MMPs include ECM remodeling and
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cytokines and chemokines [52]. Mmp7 is unique among
the MMPs in that its expression in the mammary gland is
largely restricted to the glandular epithelium [53]. A role
for Mmp7 in mammary gland development is suggested by
a study that demonstrated that expression of MMP7 in the
mammary epithelium of nulliparous mice under control of
the mouse mammary tumor virus (MMTV) promoter
induced production of milk proteins, suggesting MMP7
may play a role in mammary gland differentiation [54].
Other studies support a role of Mmp7 in mammary cancer
development and/or progression. For example, expression
of an MMTV-MMP7 transgene in the mammary epithe-
lium resulted in development of hyperplastic alveolar
nodules in a large fraction of aged multiparous mice and
shortened the time to onset of mammary tumors in mice
that also expressed an MMTV-Neu transgene [53]. More-
over, single nucleotide polymorphisms inMMP7 have been
associated with disease free and/or overall survival in two
breast cancer case control studies [55,56]. Mmp9 is
expressed by the mammary epithelium, stromal fibroblasts
and infiltrating immune/inflammatory cells. The highest
levels of Mmp9 expression in the mammary gland occur
during pregnancy and involution [57,58]. However, the
roles of Mmp9 at these developmental stages are not well
defined. Mmp9 contributes to mammary cancer metastasis
in mouse models and nucleotide variants within MMP9
have been associated with breast cancer metastasis in
humans [59,60]. Interestingly, Mmp9 has been demon-
strated to form a binary complex with Lcn2, leading to
activation and stabilization of this matrix metalloproteinase
[61-64]. These data suggest a potential mechanism for the
enhanced activation of Mmp9 observed in the mammary
glands of E2 treated BN rats.
Comparison of gene expression profiles for mammary
glands from E2 treated ACI and BN rats also revealed
differential expression of many genes that encode proteins
that reside on the cell surface and function in cell-cell or
cell-ECM interactions. One such gene, Cd44, was
observed to be expressed at an approximate 10-fold higher
level in BN rats than in ACI rats. Cd44 is expressed by the
myoepithelium in developing mammary gland and by
luminal epithelium in adult mouse mammary gland and
human breast [65]. Cd44 null mice exhibit a lactation
defect which appears to result from reduced activation of
heparin binding epidermal growth factor (HB-EGF) and
downstream signaling through ErbB4 [66]. Cd44 null mice
also exhibit delayed ductal outgrowth and small TEBs and
these phenotypes were attributed to aberrant interactions
between myoepithelium and luminal epithelium [65].
Multiple studies have demonstrated a physical interaction
between CD44 and Spp1 in a wide variety of cell types,
including breast cancer cells, which alters an array of
cellular phenotypes including motility and invasiveness[67-70]. CD44 has also been demonstrated to interact
physically and functionally with Mmp7 and Mmp9 in
multiple cell types, and by doing so enhances the activities
of Mmp7 and Mmp9 on specific substrates within the
extracellular environment [66,71-73]. Interestingly, the
interaction between CD44 and Mmp9 in PC3 prostate
cancer cells has been demonstrated to be induced by Spp1
[74]. CD24 and CD52 were observed to be expressed at
higher levels in mammary glands from E2 treated ACI
rats, relative to BN rats. CD24 encodes a cell surface
glycoprotein that has emerged as a marker for mammary
stem cells [75,76]. In the mouse mammary gland, Cd24 is
expressed in the luminal epithelium and to a lesser extent
in the basal epithelium [77,78]. Mice that are homozygous
for a Cd24 null allele exhibit accelerated ductal elongation
and increased branching morphogenesis in the mammary
gland [78]. CD52, which is paralagous to CD24, is
expressed by lymphocytes and other types of immune
cells. Virtually nothing is known regarding the role of
CD52 in mammary gland development or function.
Ongoing studies are focused on identifying and quantify-
ing the cell types in the mammary glands of ACI and BN
rats that express these different proteins.
We hypothesize that variation in a subset of the cellular
and molecular phenotypes described herein is heritable
and underlies the differing susceptibilities of the ACI
and BN rats to E2-induced mammary cancer. We are
currently testing this hypothesis by evaluating these
phenotypes in a panel of unique congenic rat strains that
were developed to characterize the QTL that were identi-
fied as genetic determinants of susceptibility to E2-
induced mammary cancer in intercrosses between
susceptible ACI and resistant BN rats [22,23]. Our work-
ing model is that genetic variants within the Emca QTL
impact expression of genes that function downstream of
E2 and progesterone to control proliferation, survival
and/or differentiation within the mammary epithelium
and/or the cellular composition of the stroma and
thereby influence susceptibility to E2-induced mammary
cancer. Supporting this model is a recently published
study in which it was demonstrated that congenic rats
that harbor, on the ACI genetic background, BN alleles
across the Emca8 locus on rat chromosome 5 exhibited
significantly reduced susceptibility to E2-induced mam-
mary cancer that was accompanied by reduced expres-
sion in the mammary gland of Pgr, Wnt4 and Cd52 and
increased expression of Spp1, relative to E2 treated ACI
rats [24]. We further hypothesize that variation in the dif-
ferent cellular and molecular phenotypes observed in E2
treated ACI and BN rats is representative of variation
that would exist within the genetically heterogeneous hu-
man population. For example, the difference in mam-
mary epithelial density exhibited by E2 treated ACI and
BN rat may be analogous to variation in breast
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modified by estrogens as well as other hormonal, genetic
and environmental factors and has been strongly associ-
ated with breast cancer risk. Additional studies are re-
quired to establish cause and effect relationships between
the cellular, molecular and mammary cancer susceptibility
phenotypes in the rat and to translate the knowledge gained
to humans.
Conclusions
The mammary glands of susceptible ACI and resistant
BN rats exhibited marked quantitative and qualitative
differences in their cellular and molecular responses to
E2.
The luminal epithelium of ACI rats exhibited a rapid
and sustained proliferative response to E2, resulting in
lobuloalveolar hyperplasia and increased epithelial density.
By contrast, the epithelium of BN rats exhibited responses
indicative of differentiation to secretory epithelium, as well
as luminal ectasia and associated changes in the ECM.
Comparison of gene expression profiles for mammary
glands of E2 treated ACI and BN rats revealed differences
in expression of multiple genes whose protein products
are required for normal mammary gland development,
differentiation and milk production, regulation of the
extracellular environment, and cell-cell or cell-ECM
interactions. Ongoing studies are focused on defining
the relationships between these cellular and molecular
phenotypes and the genetically determined differences
in susceptibility of ACI and BN rats to E2-induced
mammary cancer.
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